M H Rapaport

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint A descriptive analysis of minor depression
    Mark Hyman Rapaport
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, 92037, USA
    Am J Psychiatry 159:637-43. 2002
  2. ncbi request reprint Celecoxib augmentation of continuously ill patients with schizophrenia
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles Department of Psychiatry, Geffen School of Medicine, University of California Los Angeles 90045, USA
    Biol Psychiatry 57:1594-6. 2005
  3. ncbi request reprint Escitalopram continuation treatment prevents relapse of depressive episodes
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 65:44-9. 2004
  4. ncbi request reprint Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder
    Lewis L Judd
    Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
    Am J Psychiatry 161:1864-71. 2004
  5. ncbi request reprint Quality-of-life impairment in depressive and anxiety disorders
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Thalians Mental Health Center C 301, Los Angeles, CA 90048, USA
    Am J Psychiatry 162:1171-8. 2005
  6. ncbi request reprint Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment
    M H Rapaport
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla 92037, USA
    J Affect Disord 48:227-32. 1998
  7. ncbi request reprint Immune parameters in rapid cycling bipolar patients before and after lithium treatment
    M H Rapaport
    Department of Psychiatry, University of California, San Diego, USA
    J Psychiatr Res 33:335-40. 1999
  8. ncbi request reprint Panic disorder
    M H Rapaport
    Department of Psychiatry, University of California at San Diego and Psychiatric Service San Diego Veterans Affairs Healthcare System, 8950 La Jolla Drive, La Jolla, CA 92037, USA
    Curr Psychiatry Rep 3:295-301. 2001
  9. ncbi request reprint Is placebo response the same as drug response in panic disorder?
    M H Rapaport
    Psychopharmacology Research Program, Department of Psychiatry, University of California, San Diego, La Jolla 92037, USA
    Am J Psychiatry 157:1014-6. 2000
  10. ncbi request reprint Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines
    M H Rapaport
    Department of Psychiatry, University of California at San Diego, La Jolla, USA
    J Clin Psychopharmacol 21:104-7. 2001

Collaborators

Detail Information

Publications37

  1. ncbi request reprint A descriptive analysis of minor depression
    Mark Hyman Rapaport
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, 92037, USA
    Am J Psychiatry 159:637-43. 2002
    ..The authors provide a detailed clinical description of minor depression: its symptoms, level of disability, stability, and relationship to patient and family history of major depressive disorder...
  2. ncbi request reprint Celecoxib augmentation of continuously ill patients with schizophrenia
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles Department of Psychiatry, Geffen School of Medicine, University of California Los Angeles 90045, USA
    Biol Psychiatry 57:1594-6. 2005
    ..We hypothesized that celecoxib augmentation therapy would improve psychopathology ratings compared with placebo...
  3. ncbi request reprint Escitalopram continuation treatment prevents relapse of depressive episodes
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 65:44-9. 2004
    ..Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment...
  4. ncbi request reprint Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder
    Lewis L Judd
    Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
    Am J Psychiatry 161:1864-71. 2004
    ..Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder...
  5. ncbi request reprint Quality-of-life impairment in depressive and anxiety disorders
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Thalians Mental Health Center C 301, Los Angeles, CA 90048, USA
    Am J Psychiatry 162:1171-8. 2005
    ....
  6. ncbi request reprint Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment
    M H Rapaport
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla 92037, USA
    J Affect Disord 48:227-32. 1998
    ..Study patients were compared and contrasted with archival data from a sample of the general population measured by the Medical Outcome Survey Short Form 36...
  7. ncbi request reprint Immune parameters in rapid cycling bipolar patients before and after lithium treatment
    M H Rapaport
    Department of Psychiatry, University of California, San Diego, USA
    J Psychiatr Res 33:335-40. 1999
    ..Lithium treatment increased IL-2, SIL-2RS and SIL-6RS in normal volunteers. These data suggest that rapid cycling bipolar patients may have mild immune activation which seems to normalize with lithium treatment...
  8. ncbi request reprint Panic disorder
    M H Rapaport
    Department of Psychiatry, University of California at San Diego and Psychiatric Service San Diego Veterans Affairs Healthcare System, 8950 La Jolla Drive, La Jolla, CA 92037, USA
    Curr Psychiatry Rep 3:295-301. 2001
    ..The authors focus on peer-reviewed data and on pragmatic clinical approaches that may help patients suffering from panic disorder...
  9. ncbi request reprint Is placebo response the same as drug response in panic disorder?
    M H Rapaport
    Psychopharmacology Research Program, Department of Psychiatry, University of California, San Diego, La Jolla 92037, USA
    Am J Psychiatry 157:1014-6. 2000
    ..The authors used seven definitions of response in panic disorder to compare patient-rated improvements in quality of life between patients with panic disorder who responded to sertraline and those who responded to placebo...
  10. ncbi request reprint Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines
    M H Rapaport
    Department of Psychiatry, University of California at San Diego, La Jolla, USA
    J Clin Psychopharmacol 21:104-7. 2001
    ..Sertraline is both well-tolerated and has significant efficacy in patients with panic disorder, including the subset of patients with panic disorder who have previously been treated with BZs...
  11. ncbi request reprint Sertraline treatment of panic disorder: response in patients at risk for poor outcome
    M H Pollack
    Department of Psychiatry, Massachusetts General Hospital, Boston 02114 7541, USA
    J Clin Psychiatry 61:922-7. 2000
    ..No published research has systematically examined the differential antipanic efficacy of selective serotonin reuptake inhibitors in patients at high risk for poor outcome...
  12. ncbi request reprint Prevalence, recognition, and treatment of comorbid depression and anxiety
    M H Rapaport
    Department of Psychiatry, University of California, and the San Diego Veterans Affairs Healthcare System, 92037, USA
    J Clin Psychiatry 62:6-10. 2001
    ..Finally, current data on treatment will be discussed, with a focus on optimal treatment approaches and duration of treatment...
  13. ncbi request reprint Sleep estimation from wrist activity in patients with major depression
    G Jean-Louis
    Circadian Pacemaker Laboratory, Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, Box 0667, La Jolla, CA 92093 0667, USA
    Physiol Behav 70:49-53. 2000
    ..These findings suggest that scoring criteria optimized on wrist-activity data of healthy young adults may not produce optimal results for patients characterized with major depressive episodes...
  14. ncbi request reprint Sertraline treatment of panic disorder: results of a long-term study
    M H Rapaport
    Department of Psychiatry, University of California at San Diego and Psychiatric Service San Diego Veterans, Affairs Healthcare System, 8950 Villa La Jolla Dr, La Jolla, CA 92037, USA
    Acta Psychiatr Scand 104:289-98. 2001
    ..15.7% placebo; P=0.013) occurring at significantly higher rates. CONCLUSION: Long-term sertraline treatment was effective in preventing relapse of panic disorder, well tolerated and associated with minimal discontinuation symptoms...
  15. ncbi request reprint Preliminary evidence of an association between increased REM density and poor antidepressant response to partial sleep deprivation
    C Clark
    Department of Psychiatry 9116A University of California at San Diego 92093, USA
    J Affect Disord 59:77-83. 2000
    ....
  16. ncbi request reprint An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder
    J C Gillin
    University of California and VA San Diego Healthcare System, 92161, USA
    J Clin Psychiatry 62:789-96. 2001
    ..To our knowledge, this is the first polysomnographic study of treatment in patients with PTSD...
  17. ncbi request reprint Neonaticide in the city of Rio de Janeiro: forensic and psycholegal perspectives
    M V Mendlowicz
    Institute of Psychiatry, Federal University of Rio de Janeiro, Brazil
    J Forensic Sci 44:741-5. 1999
    ..82, d.f. = 1, p < .001), increased referral for psychiatric assessment (chi 2 = 3.85, d.f. = 1, p = .05), and greater frequency of cases where statute of limitations was expired (chi 2 = 3.88, d.f. = 1, p = .049)...
  18. ncbi request reprint Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores
    Leslie A Lenert
    VA San Diego Healthcare System, San Diego, CA 92161, USA
    Schizophr Res 71:155-65. 2004
    ..This complicates the use of standard cost-effectiveness analysis to set priorities for health resource allocation...
  19. ncbi request reprint TEMPS-A: validation of a short version of a self-rated instrument designed to measure variations in temperament
    Hagop S Akiskal
    Department of Psychiatry, International Mood Center, University of California, San Diego, VA Psychiatry 116A, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    J Affect Disord 85:45-52. 2005
    ..Further item wording and selection were achieved at a later stage through an iterative process that incorporated feedback from clinicians, researchers, and research volunteers...
  20. ncbi request reprint Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration
    B L Brody
    Department of Ophthalmology, University of California, San Diego, La Jolla, California 92093-0946, USA
    Ophthalmology 108:1893-900; discussion 1900-1. 2001
    ..Over and above depression, visual acuity aided in predicting vision-specific disability. Treatment strategies that teach patients to cope with vision loss should be developed and evaluated...
  21. ncbi request reprint Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder
    J A Gladsjo
    Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla 92037, USA
    J Clin Psychopharmacol 21:131-8. 2001
    ..These findings call into question the assumption that long-term benzodiazepine therapy produces significant neuropsychologic deficit in patients with diagnosed anxiety disorders...
  22. ncbi request reprint Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Biol Psychiatry 58:347-54. 2005
    ..Vagus nerve stimulation (VNS) alters both concentrations of neurotransmitters or their metabolites and functional activity of central nervous system regions dysregulated in mood disorders. An open trial has suggested efficacy...
  23. ncbi request reprint The effects of lithium on ex vivo cytokine production
    M H Rapaport
    Psychopharmacology Research Program, Department of Psychiatry, University of California, San Diego, California 92037, USA
    Biol Psychiatry 50:217-24. 2001
    ..The study suggests that lithium may have complex time-dependent effects on immune function...
  24. pmc A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22
    J R Kelsoe
    Department of Psychiatry, University of California at San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 98:585-90. 2001
    ..The regions on 22q, 13q, and 10q have been implicated in studies of schizophrenia, suggesting the possible presence of susceptibility genes common to both disorders...
  25. ncbi request reprint Sleep and sleep electroencephalogram in depressed patients treated with phenelzine
    H P Landolt
    University of California at San Diego, Mental Health Clinical Research Center, Psychiatry Service 116 A, VAMC, 3350 La Jolla Village Dr, San Diego, CA 92161
    Arch Gen Psychiatry 58:268-76. 2001
    ..Use of the monoamine oxidase inhibitor phenelzine sulfate can eliminate REM sleep. We studied the relation between REM sleep suppression and antidepressant response and the effect of phenelzine therapy on sleep EEG power spectra...
  26. ncbi request reprint Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment
    Mark H Rapaport
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92037, USA
    J Clin Psychiatry 63:59-65. 2002
    ..The goal of the current study was to characterize the quality of life (QOL) and functional impairment associated with posttraumatic stress disorder (PTSD) and to report the QOL/functional response over the course of long-term treatment...
  27. ncbi request reprint Quality of life in geriatric patients with mood and anxiety disorders
    Rachel E Maddux
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    CNS Spectr 8:35-47. 2003
    ....
  28. ncbi request reprint Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins
    M H Rapaport
    Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla 92093
    Eur Arch Psychiatry Clin Neurosci 243:7-10. 1993
    ..08) showed trends towards higher serum SIL-2R levels than their respective control groups. These data contribute to the growing body of evidence that immune activation is associated with some forms of schizophrenia...
  29. ncbi request reprint Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder
    Mark H Pollack
    Anxiety Disorders Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, WAC 812, 15 Parkman Street, Boston, MA 02114, USA
    J Psychiatr Res 36:229-36. 2002
    ....
  30. ncbi request reprint The effectiveness of atypical antipsychotic medications in depressive disorders
    Waguih William Ishak
    Department of Psychiatry, Cedars Sinai Medical Center and University of California at Los Angeles, 8730 Alden Drive, Thalians C 301, Los Angeles, CA 90048, USA
    Curr Psychiatry Rep 6:422-4. 2004
    ....
  31. ncbi request reprint Efficacy of controlled-release paroxetine in the treatment of late-life depression
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, 8730 Alden Dr, Suite C301, Los Angeles, CA 90048, USA
    J Clin Psychiatry 64:1065-74. 2003
    ..Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition...
  32. ncbi request reprint Amnesia and neonaticide
    Mauro V Mendlowicz
    Am J Psychiatry 159:498-9. 2002
  33. ncbi request reprint The effects of celecoxib augmentation on cytokine levels in schizophrenia
    Catherine J Bresee
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90045, USA
    Int J Neuropsychopharmacol 9:343-8. 2006
    ..These elevations did not persist by week 8. Overall, celecoxib does not significantly modify cytokine levels in medicated schizophrenia subjects...
  34. ncbi request reprint Classification and treatment of sub-threshold depression
    Sarah K Rowe
    Cedars Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90048, USA
    Curr Opin Psychiatry 19:9-13. 2006
    ..The purpose of this review is to evaluate the recent literature on depressive spectrum disorders...
  35. ncbi request reprint Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuropsychopharmacology 31:2505-13. 2006
    ..1 and 64.1%, respectively (p < or = 0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study...
  36. ncbi request reprint Translating the evidence on atypical depression into clinical practice
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Clin Psychiatry 68:e11. 2007
    ..A newer MAOI, the transdermal formulation of selegiline, may provide all of the efficacy of the older MAOIs in treating atypical depression without causing as great of adverse events and no diet restrictions...
  37. ncbi request reprint Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art
    Mark Hyman Rapaport
    Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Psychiatry 68:42-6. 2007
    ..However, MAOIs have been well established as an effective intervention for people with treatment-resistant depression, and transdermal formulations may provide a valuable therapeutic option and eliminate the drug-food interaction...